Incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostatic cancer;Incidence de la variabilité du rapport PSA libre/PSA total sur le diagnostic précoce du cancer de prostate

Progres en Urologie

Volumn 7, Issue 3, 1997, Pages 455-461

  De la Taille, Alexandre ^a   Houlgatte, Alain ^a   Patrice Houdelette, D ^a   Berlizot, Patrick ^a   Fournier, Robert ^a   Ricordel, Ivan ^b  

^a Clinique Urologie   (France)

^b AP HP   (France)

Author keywords

Benign prostatic hyperplasia; Prostate specific antigen, diagnosis; Prostatic cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; ANALYTICAL EQUIPMENT; BIOPSY; BLOOD; CANCER STAGING; COMPARATIVE STUDY; FOLLOW UP; HUMAN; INCIDENCE; MALE; MIDDLE AGED; PATHOLOGY; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PROSTATE TUMOR; RECTUM; REFERENCE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; BIOPSY; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PHYSICAL EXAMINATION; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REAGENT KITS, DIAGNOSTIC; RECTUM; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0031158305     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. BENSON M.C., WHANG I S., OLSSON C.A., et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol., 1992, 147, 817-821.
2. CATALONA WJ, HUSON MA, SCARDINO PT, et al.Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer : receiver operating characteristic curves. J Urol., 1994, 152, 2037-2042.
3. CATALONA W J.,RICHIE J.P., DEKERNION J.B., et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer receiver operating characteristic curves. J Urol., 1994, 152, 2031-2036.
4. CATALONA W.J., SMITH D.S, WOLFERT R L., et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 1995, 275(15), 1214-1220.
5. CATALONA W.J., RICHIE J.P, AHMANN F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer : results of a multicenter clinical trial of 6630 men. J. Urol., 1994, 151, 1283-1289
6. CHAUTARD D.,DAVER A., BALI B et al Evaluation de la mesure de l'antigène spécifique de prostate (PSA) sous sa forme libre sérique Prog. Urol., 1996, 6, 368-373.
7. CHEN Y.T., LUDERER A.A., THIEL R.P., CARLSON G., CUNY C.L , SORIANO T.F. Using proportions of free to total prostatic specific antigen age and total prostatic specific antigen to predict the probability of prostate cancer. Urology, 1996, 47, 518-524.
8. CHRISTENSSON A.,BJORK T., NILSSON O. et al Serum prostate specific antigen complexed to alpha 1 antichymotrypsin as an indicator of prostate cancer. J. Urol., 1993, 150, 100-105.
9. CRAWFORD E.D., DEANTONI E.P., ETZIONI R., et al. Serum prostate specific antigen and digital rectal examination for early detection of prostate cancer in a national community based program. Urology, 1996, 47, 863-869.
10. DEMURA T.,SHINOHARA N., TANAKA M., et al. The proportion of free to total prostate specific antigen. Cancer, 1996, 77, 1137-1143.
11. ELGAMAL A.A., CORNILLIE F.K., VAN POPPEL H.P., VAN DE VOORDE W.M., MCCABE R., BAERT L.V. Free to total prostatic antigen ratio as a single test for detection of significant stage TIC prostate cancer. J Urol., 1996, 156(3), 1047-1049.
12. FROSCHERMAIER SE, PILARSKY CP, WIRTH MP.Clinical significance of the determination of noncomplexed prostate specific antigen as a marker for prostate carcinoma. Urology, 1996, 47, 525-528.
13. HANLEY J.A., MC NEIL B.J. The meaning and use of the area under a Receiver Operating Characteristic (ROC) curve. Radiology, 1982, 143, 29-36.
14. HANLEY J.A., MC NEIL B.J. A method of comparing the areas under Receiver Operating Characteristic curves derived from the same case. Radiology, 1983, 148, 839-843.
15. JACOBSEN S.J., KLEE G.G., LILJA H., et al. Stability of serum prostate specific antigen determination across laboratory, assay, and storage time. Urology, 1995, 45, 447-453.
16. LERNER S.E., JACOBSEN S.J., LILJA H. et al. Free, complexed ant total serum prostate specific antigen concentrations and their proportions in predicting stage, grade and desoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology, 1996, 48, 240-248.
17. LILJA H , CHRISTENSSON A.,DAHLEN U. et al. Prostate specific antigen in serum occurs predominantly in complex with alpha 1 antichymotrypsin. Clin. Chem., 1991, 37, 1618-1625.
18. LUDERER A.A., CHEN Y.T., SORIANO T.F. et al. Measurement of the proportion of free to total prostate specific antigen improve diagnostic performance of prostate specific antigen in the diagnostic gray zone of total prostate specific antigen. Urology, 1995, 46, 187-194.
19. MARLEY G.M., MILLER M.C., KATTAN M.W. et al. Free and complexed prostate specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urology, 1996, 48, 16-22.
20. MORGAN T.O., MCLEOD D.G., LEIFER E.S., MURPHY G.P., MOUL J.W. Prospective use of free prostate specific antigen to avoid repeat prostate biopsies in men with elevated total prostate specific antigen. Urology, 1996, 48, 76-80.
21. OESTERLING J.E., JACOBSEN S.J., KLEE G.G. et al. Free, complexed and total serum prostate specific antigen, the establishment of appropriate reference ranges for their concentrations and ratios. J. Urol., 1995, 154, 1090-1095.
22. OESTERLING J.E., JACOBSEN S.J., CHUTE C.G., GUESS H.A., GIRMAN C.J., PANSER L.A., LIEBER M.M. Serum prostate specific antigen in a community based population of healthy men Establishment of age specific reference range J.A.M.A., 1993, 270, 860-871.
23. OESTERLING J.E., WOJNO K.J., VASHI A. et al. Determination of the reflex range and appropriate outpoints for percent free PSA in 13 men referred for protate evaluation using the AxSYM system. J. Urol., 1996, 155, 370A.
24. PANNEK J.,SUBONG E.N., JONES K.A. et al. The role of free/total prostatic specific antigen ratio in the prediction of final Pathologic stage for men with clinically localized prostate cancer. Urology, 1996, 48, 51-54.
25. PARTIN A.W., CATALONA W.J., SOUTHWICK P.C., SUBONG E.N., GASIOR G.H., CHAN D.W. Analysis of percent free prostate specific antigen (PSA) for prostate cancer detection, influence of total PSA, prostate volume and age. Urology, 1996, 48, 62-66.
26. PEARSON J.A , LUDERER A.A., METTER E.J., PARTIN A.W., CHAN D.W., FOZARD J.L., CARTER H.B., Longitudinal analysis of serial measurement of free and total PSA among men woth and whitout prostatic cancer. Urology, 1996, 48, 4-9.
27. PRESTIGIACOMO A.F., STAMEY T.A. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J. Urol., 1997, 157, 189-194.
28. RAVERY V.Le PSA libre. Prog. Urol., 1997, 7, 88-91..
29. ROEHRBORN C.G., GREGORY A., MC CONNELL J.D., SAGALOWSKY A.I., WIAMS F.H. Comparison of three assays for total serum prostate specific antigen and percentage of free prostate specific antigen in predicting prostate histology. Urology, 1996, 48, 23-32.
30. SCHMID H.P., RAVERY V., BILLEBAUD T. et al. Early detection of prostate cancer in men with prostatism and intermediate prostate specific antigen levels Urology. 1996, 47, 699-703.
31. SMITH D.S , CATALONA W.J. Rate of chance in serum prostate specific antigen levels as a method for prostate cancer detection. J. Urol., 1994, 152, 1163-1167.
32. STAMEY T A.,YANG N , HAY A.R., MC NEAL J.E., FREIHA F.S., REDWINE E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med., 1987, 317, 909-911.
33. STENMAN U.H., LEINONEN J., ALFTHAN H., et al. A complex between prostate specific antigen and alpha 1 antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer, assay of the complex improves clinical sensibility for cancer. Cancer Research, 1991, 51, 222-226.
34. VAN CANGH P.J., DE NAYER P., DE VISHER L. et al. Free to total prostate specific antigen ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia in the diagnostic gray zone of 1.8 to 10.0 ng/ml total PSA. Urology, 1996, 48, 67-70.
35. WOODRUM D.,FRENCH C., BLAIR SHAMEL L.. Stability of free prostate specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology, 1996, 48, 33-39.